Brainsway has reported additional interim results of a clinical trial being conducted at the Ichilov Medical Center in Israel to evaluate the efficacy of a deep transcranial magnetic stimulation (TMS) system in the treatment of Alzheimer’s disease.

The interim study included 24 patients who were divided into three groups: a sham stimulation control group, a low-frequency treatment group and a high-frequency treatment group.

Each subject received treatment over eight weeks, and the efficacy of the treatment was evaluated both during the trial and over the course of the subsequent eight-week period.

Treatment using deep TMS was well-tolerated by all subjects, with no side-effects.

Efficacy was evaluated using the Alzheimer’s Disease Assessment Scale – Cognitive test and a quality-of-life scale.

The results suggest that high-frequency treatment leads to improvement on Alzheimer’s disease assessment scales, whereas low-frequency and sham treatment do not.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.